Failure of a repeat course of cyclooxygenase inhibitor to close a PDA is a risk factor for developing chronic lung disease in ELBW infants.

The article offers information on optimal treatment regimen for managing a persistent patent ductus arteriosus (PDA) in extremely low birth weight (ELBW) infants. It states that 71.4 percent of those who survived, received 1-3 courses of cyclooxygenase inhibitor(COI) treatment for a symptomatic PDA. A total of 40 percent failed COI treatment and underwent PDA ligation. The failure of a repeat course of COI to close a PDA is a risk factor for developing chronic lung disease CLD in ELBW infants.